Investors are on the edge of their collective seats, hoping that Gen-Probe
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Gen-Probe with 10 of 19 analysts rating it hold. Analysts don't like Gen-Probe as much as competitor Bio-Rad Laboratories overall. Four out of five analysts rate Bio-Rad Laboratories a buy compared to nine of 19 for Gen-Probe. Analysts still rate the stock a hold, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $140.6 million in revenue this quarter. That would represent a rise of 6.1% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.54 per share. Estimates range from $0.53 to $0.58.
What our community says:
CAPS All-Stars are solidly behind the stock with 98.6% granting it an "outperform" rating. The community at large agrees with the All-Stars with 96.3% assigning it a rating of "outperform." Fools have embraced Gen-Probe, though the message boards have been quiet lately with only 56 posts in the past 30 days. Despite the majority sentiment in favor of Gen-Probe, the stock has a middling CAPS rating of three out of five stars.
Gen-Probe's profit has risen year over year by an average of 3.1% over the past five quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Gen-Probe now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.